Use cases by solution area
Solution areas ranked by the number of public disclosures in each one.
Counts reflect public disclosure, not actual use.
274 entries · 45 companies 349 entries · 49 companies
| Area | Entries | Companies | Share | Share in production | Stage |
|---|---|---|---|---|---|
| Enterprise, IT and knowledge work | 43 | 24 | 15.7% | 83.7% | Production 36, Pilot 1, Announced 2, Stage unclear 4 |
| Clinical development | 39 | 28 | 14.2% | 46.2% | Production 18, Pilot 1, Announced 10, Stage unclear 10 |
| AI drug discovery | 38 | 23 | 13.9% | 71.1% | Production 27, Pilot 0, Announced 5, Stage unclear 6 |
| Manufacturing and quality | 35 | 17 | 12.8% | 54.3% | Production 19, Pilot 4, Announced 4, Stage unclear 8 |
| Other | 34 | 23 | 12.4% | 52.9% | Production 18, Pilot 0, Announced 11, Stage unclear 5 |
| Commercial and medical affairs | 22 | 16 | 8.0% | 59.1% | Production 13, Pilot 2, Announced 4, Stage unclear 3 |
| Regulatory, medical writing and pharmacovigilance | 19 | 15 | 6.9% | 52.6% | Production 10, Pilot 2, Announced 1, Stage unclear 6 |
| AI infrastructure | 16 | 14 | 5.8% | 50.0% | Production 8, Pilot 0, Announced 6, Stage unclear 2 |
| Diagnostics and clinical decision support | 14 | 11 | 5.1% | 21.4% | Production 3, Pilot 1, Announced 7, Stage unclear 3 |
| Supply chain and distribution | 10 | 8 | 3.6% | 70.0% | Production 7, Pilot 0, Announced 1, Stage unclear 2 |
| AI governance and enablement | 4 | 3 | 1.5% | 100.0% | Production 4, Pilot 0, Announced 0, Stage unclear 0 |
Entries by area sum to 274.
| Area | Entries | Companies | Share | Share in production | Stage |
|---|---|---|---|---|---|
| Research partnerships | 75 | 32 | 21.5% | 5.3% | Production 4, Pilot 0, Announced 66, Stage unclear 5 |
| Enterprise, IT and knowledge work | 43 | 24 | 12.3% | 83.7% | Production 36, Pilot 1, Announced 2, Stage unclear 4 |
| Clinical development | 39 | 28 | 11.2% | 46.2% | Production 18, Pilot 1, Announced 10, Stage unclear 10 |
| AI drug discovery | 38 | 23 | 10.9% | 71.1% | Production 27, Pilot 0, Announced 5, Stage unclear 6 |
| Manufacturing and quality | 35 | 17 | 10.0% | 54.3% | Production 19, Pilot 4, Announced 4, Stage unclear 8 |
| Other | 34 | 23 | 9.7% | 52.9% | Production 18, Pilot 0, Announced 11, Stage unclear 5 |
| Commercial and medical affairs | 22 | 16 | 6.3% | 59.1% | Production 13, Pilot 2, Announced 4, Stage unclear 3 |
| Regulatory, medical writing and pharmacovigilance | 19 | 15 | 5.4% | 52.6% | Production 10, Pilot 2, Announced 1, Stage unclear 6 |
| AI infrastructure | 16 | 14 | 4.6% | 50.0% | Production 8, Pilot 0, Announced 6, Stage unclear 2 |
| Diagnostics and clinical decision support | 14 | 11 | 4.0% | 21.4% | Production 3, Pilot 1, Announced 7, Stage unclear 3 |
| Supply chain and distribution | 10 | 8 | 2.9% | 70.0% | Production 7, Pilot 0, Announced 1, Stage unclear 2 |
| AI governance and enablement | 4 | 3 | 1.1% | 100.0% | Production 4, Pilot 0, Announced 0, Stage unclear 0 |
Entries by area sum to 349.